T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Engineering

Background:

• Advanced prostate cancer (PCa) has limited treatment options, with immune checkpoint inhibitors showing minimal efficacy due to an "immune-cold" microenvironment.
• T-cell engagers (TCEs), bispecific antibodies targeting CD3 on T-cells and tumor-associated antigens (TAAs), offer potent, MHC-independent cytotoxicity against PCa.
• Early PSMA-targeted TCEs demonstrated proof-of-concept, while newer agents targeting STEAP1 show enhanced objective responses, indicating progress in target selection and molecular design.

Purpose of the Study:

• To review the current landscape of TCEs targeting PSMA, STEAP1, and DLL3 in prostate cancer.
• To critically evaluate emerging clinical evidence and identify key challenges and future directions for TCE therapy in PCa.
• To connect advancements in molecular engineering with clinical outcomes and therapeutic potential.

Main Methods:

• Literature review and synthesis of emerging clinical data on TCEs in advanced prostate cancer.
• Critical evaluation of molecular engineering strategies, including affinity tuning, masking, and multispecific constructs.
• Discussion of toxicity mitigation, biomarker-driven patient selection, and combination therapy approaches.

Main Results:

• STEAP1-targeting TCEs, like Xaluritamig, demonstrate more substantial objective responses compared to earlier PSMA-targeted agents.
• Key challenges for TCEs include cytokine release syndrome (CRS), limited response durability, and antigen escape.
• Sophisticated engineering and combination therapies are crucial for overcoming resistance mechanisms and enhancing efficacy.

Conclusions:

• TCEs are emerging as a significant therapeutic pillar for advanced prostate cancer, offering potent anti-tumor activity.
• Overcoming challenges related to safety, durability, and antigen escape through innovative engineering and strategic combinations is essential for realizing TCEs' full potential.
• Biomarker-driven patient selection and integration with existing treatments will be critical for optimizing TCE therapy outcomes in PCa.